Page 89 - Priority Review News Today

The FDA has accepted for Priority Review the BLA for the oral microbiome therapeutic SER-109 for the treatment of recurrent C. difficile infection.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that the Independent Data Monitoring Committee (IDMC) for the randomised, controlled Phase IIb TACTI-003 trial has ...

SAN DIEGO, Oct. 24, 2022 /PRNewswire/ -- Invivoscribe is pleased to announce that they have filed a supplemental Pre-Market Approval (sPMA) submis...

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted pediatric exclusivity...

Alzheimer's treatments could make a big winner of these stocks.

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

Cui bono is Latin for "Who benefits?" Its the sister phrase of "sequi pecuniam/follow the money" and the orphan of "plebes/the people." All roads used to lead to Rome. Today, they lead to chosen industry. There are many sayings about...

Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront payment, a second payment

Jazz to obtain exclusive development and commercialization rights in key markets including the U.S., Europe and Japan Zymeworks to receive $50 million upfront...

The Food and Drug Administration (FDA) has extended the review periods for 2 investigational products: sparsentan and tofersen.